Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) - Concepedia

Concepedia

Publication | Open Access

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)

DOI Full Paper Access

85

Citations

26

References

2023

Year

Maryam Oskoui, John Day, Nicolas Deconinck, Elena Mazzone, A. Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie Goemans, Janbernd Kirschner,

Journal of Neurology

References

	Year	Citations

Page 1